Niacin for primary and secondary prevention of cardiovascular events. - Wikidata - wikimedia - TriplyDB

Niacin for primary and secondary prevention of cardiovascular events.

Niacin for primary and secondary prevention of cardiovascular events.

http://www.wikidata.org/entity/Q34682221

about

Biochemical targets of drugs mitigating oxidative stress via redox-independent mechanisms.New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.

P2860

Q46269173-3ECAE2CD-8BB5-4B75-9EF7-13062E6A3C55 Q50044216-ABBB03DB-E6B3-420E-B160-EAAC14ECAA75

P2860

Niacin for primary and secondary prevention of cardiovascular events.

http://www.wikidata.org/entity/Q34682221

description

2017 nî lūn-bûn

@nan

2017 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Niacin for primary and secondary prevention of cardiovascular events.

@ast

Niacin for primary and secondary prevention of cardiovascular events.

@en

Niacin for primary and secondary prevention of cardiovascular events.

@nl

type

label

Niacin for primary and secondary prevention of cardiovascular events.

@ast

Niacin for primary and secondary prevention of cardiovascular events.

@en

Niacin for primary and secondary prevention of cardiovascular events.

@nl

prefLabel

Niacin for primary and secondary prevention of cardiovascular events.

@ast

Niacin for primary and secondary prevention of cardiovascular events.

@en

Niacin for primary and secondary prevention of cardiovascular events.

@nl

P1433

Q34682221-51646DF2-3387-4B99-970D-0C144B72B2F7

P1476

Q34682221-CDC5785F-A306-4EDF-B1C6-E7CAB7B0671D

P2093

Q34682221-0A6D00DA-D871-46B3-92B7-7D11A19D6728

Q34682221-493362D0-EC64-49BF-B44F-E899D5AC1E0A

Q34682221-915CCE79-38E4-441C-B2AB-B0119B268B1D

Q34682221-AE4DD28E-B029-4947-B33A-4565CCC3F845

Q34682221-C5A56BBC-C2CD-44A9-BF5D-9F4C4125801D

P2860

Q34682221-005B4608-ED63-4D85-9079-1AD1C8577B5F

Q34682221-046E0604-7758-43EC-B8D3-ECE8208F5EC1

Q34682221-05565DBE-F75F-40E1-B9DA-B69793E90BE8

Q34682221-058F5EA0-4198-4A69-A231-89EE272C25DF

Q34682221-06BAE4C2-E021-4C4B-AF46-AFCB3668A288

Q34682221-06F2BF84-2A96-4FF1-B0B2-86ECA71D026B

Q34682221-0B49CAD5-B817-4981-8343-075E1A5A88AE

Q34682221-0CE89285-26DB-4A30-8570-A6F3588B586C

Q34682221-0E98AD01-D5A1-42EE-ABDE-C866200957CE

Q34682221-10FAF8EC-816C-4B24-90AF-BE5AAC0B62C5

P304

Q34682221-C23C6656-DFF6-4D82-AAB3-CFB6340FE3C7

P31

Q34682221-F065D474-EA50-4E28-A553-2EA3DD3F307A

Q34682221-e51902e5-2cb9-4b02-b8ba-2ca88a07e079

P356

Q34682221-70DFBA5A-4364-46AE-AC9F-0B6E83251B85

P478

Q34682221-F499A87A-8644-4D3C-8DB2-AFD5EF54DEAE

P50

Q34682221-92CD1BE5-2811-47C1-BB97-141F9711FDCC

Q34682221-FF6CF59C-8D91-4EB2-95C1-BFD363A9B3B0

P577

Q34682221-F7320C47-4E02-476E-9035-C1F0C338D966

P698

Q34682221-363FBA87-B75C-49C8-B83B-E4C9F4E0E6C8

P932

Q34682221-12336E84-A9F9-48DF-BC2A-062290A5344E

P356

14651858.CD009744.PUB2

P1433

Cochrane Database of Systematic Reviews

P1476

Niacin for primary and secondary prevention of cardiovascular events

@en

P2093

Alain J Nordmann

http://www.w3.org/2001/XMLSchema#string

Armon Arpagaus

http://www.w3.org/2001/XMLSchema#string

Kelechi K Olu

http://www.w3.org/2001/XMLSchema#string

Matthias Briel

http://www.w3.org/2001/XMLSchema#string

Ramon Saccilotto

http://www.w3.org/2001/XMLSchema#string

P2860

Bias in meta-analysis detected by a simple, graphical test

Measuring inconsistency in meta-analyses

Quantifying heterogeneity in a meta-analysis

Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects

Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Dietary fat intake and prevention of cardiovascular disease: systematic review

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

P304

CD009744

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/14651858.CD009744.PUB2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Stefan Schandelmaier

P577

2017-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28616955

http://www.w3.org/2001/XMLSchema#string

P932

6481694

http://www.w3.org/2001/XMLSchema#string